In Vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in Human Chordoma Xenografts [RNA-seq]

We evaluated the tumor efficacy of the CDK4/6 inhibitor palbociclib in two chordoma Patient’s Derived Xenograft (PDX) models to validate and identify novel therapeutic approaches. Gene expression analysis of RNA-seq data for two chordoma PDX models (CD3 and CD7), without treatment and after palbociclib treatment.

本研究在两种脊索瘤患者来源异种移植（Patient’s Derived Xenograft, PDX）模型中，评估了细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂帕博西尼（palbociclib）的肿瘤疗效，以验证并筛选新型治疗策略。此外，针对未接受治疗及接受帕博西尼治疗后的这两种脊索瘤PDX模型（CD3与CD7）的RNA测序（RNA-seq）数据，开展了基因表达分析。